Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) of a class action securities lawsuit.

Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights – BIIB

Biogen stock has mostly trended sideways this year, but that could soon change with up to $10 billion in dry powder, an analyst said Tuesday.

Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense

NEW YORK, NY / ACCESSWIRE / July 16, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=90909&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024, inclusive (the “Class Period”), have until Monday, July 22, 2024 to seek appointment as lead plaintiff in the Biogen class action lawsuit. Captioned Gray v. Biogen Inc., No. 24-cv-01444 (D. Colo.), the Biogen class action lawsuit charges Biogen and certain of Biogen's top current and former executives with violations of the Securities Exchange Act of 1934.

INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB

NEW YORK, NY / ACCESSWIRE / July 16, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=90856&wire=1 or contact Joseph E. Levi, Esq.

Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB

Merck

Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing

Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing

LOS ANGELES , July 16, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ:BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB

NEW YORK, NY / ACCESSWIRE / July 15, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=90819&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / July 15, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=90792&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP reminds shareholders that only 7 days remain to move for lead plaintiff in a securities class action lawsuit alleging claims on behalf of investors (the “Class”) who purchased or acquired the securities of Biogen Inc. (“Biogen”) (NASDAQ: BIIB) between February 3, 2022 and February 13, 2024, inclusive (the “Class Period”). If you wish to serve as lead plaintiff for the Class, you must file papers by July 22, 2024.

BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER ALERT: Only 7 Days Remain For Investors To Move For Lead Plaintiff in Biogen Inc.

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB).

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit – BIIB

RADNOR, Pa. , July 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc. ("Biogen") (NASDAQ: BIIB).

Final Deadline Approaching for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Lead Plaintiff Deadline

NEW YORK, NY / ACCESSWIRE / July 15, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=90710&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB

NEW YORK, NY / ACCESSWIRE / July 14, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=90684&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / July 14, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=90658&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB

NEW YORK, NY / ACCESSWIRE / July 14, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=90646&wire=1 or contact Joseph E. Levi, Esq.

BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

SAN DIEGO, July 13, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024, all dates inclusive (the “Class Period”), have until July 22, 2024 to seek appointment as lead plaintiff in the Biogen class action lawsuit. Captioned Gray v. Biogen Inc., No. 24-cv-01444 (D. Colo.), the Biogen class action lawsuit charges Biogen as well as certain of Biogen's top current and former executives with violations of the Securities Exchange Act of 1934.

BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=90567&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB

RADNOR, PA / ACCESSWIRE / July 12, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the against Biogen Inc. ("Biogen") (NASDAQ:BIIB). The action charges Biogen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before July 22, 2024.

The Schall Law Firm Calls On Shareholders In Biogen Inc Who Suffered Losses To Start Conversation Be Mindful Of The Deadline In This Issue

NEW YORK , July 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB

NEW YORK, NY / ACCESSWIRE / July 11, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=90422&wire=1 or contact Joseph E. Levi, Esq.

Biogen Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - BIIB

NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP notifies investors of approaching July 22, 2024 deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired Biogen, Inc (“Biogen” or the “Company”) (NASDAQ: BIIB) securities during the period of February 3, 2022 through February 13, 2024, inclusive (“the Class Period”).

Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before July 22, 2024.

The Schall Law Firm Invites Shareholders In Biogen Inc Who Experienced Losses To Initiate Dialogue Be Aware Of The Deadline In This Matter

LOS ANGELES--(BUSINESS WIRE)--BIIB Investors Have Opportunity to Join Biogen Inc. Securities Fraud Investigation with the Schall Law Firm.

News for Biogen Stock (BIIB)